Department of Genetics & Development, Columbia University Medical Center, New York, New York 10032, USA.
Annu Rev Med. 2011;62:323-31. doi: 10.1146/annurev-med-090710-133426.
The molecular elucidation of two human skeletal dysplasias revealed that they are caused by an increase or a decrease in the synthesis of serotonin by enterochromaffin cells of the gut. This observation revealed a novel and powerful endocrine means to regulate bone mass. Exploiting these findings in the pharmacological arena led to the demonstration that inhibiting synthesis of gut-derived serotonin could be an effective means to treat low-bone-mass diseases such as osteoporosis.
两种人类骨骼发育不良的分子阐明表明，它们是由肠道肠嗜铬细胞中血清素合成的增加或减少引起的。这一观察结果揭示了一种新的、强大的内分泌调节骨量的手段。在药理学领域利用这些发现，证明抑制肠道来源的血清素合成可能是治疗低骨量疾病（如骨质疏松症）的有效手段。
